Onera

Onera operates at the intersection of medical devices, digital health, sleep diagnostics, and remote monitoring. Its core differentiation is the combination of a wireless, patch-based polysomnography system with a cloud-enabled service model rather than a single consumer sleep-tracking product. The Onera Sleep Test System is designed to capture clinical-grade data at home or in clinical settings, while PSG-as-a-Service packages hardware and digital workflow support for remote studies. The 2026 Somnoware integration strengthens the company’s position in provider infrastructure by connecting home testing with sleep-lab operations. Onera also has FDA-cleared positioning for Onera PSG and has accumulated 16 granted patents, supporting a defensible medical-device profile. Its competitive profile therefore rests more clearly on clinical-grade home testing, full-PSG breadth, and workflow integration than on consumer engagement or large-scale distribution.

Onera’s trajectory reflects a progression from technical formation to financing, clinical validation, and workflow commercialization. Founded in 2017, the company raised an initial 2018 venture round, followed by a $9.1 million Series A in 2019 and two grants in 2020. It then secured a $12.5 million Series B in 2021 and a $32.6 million Series C on Jan 16, 2024, bringing total disclosed funding to approximately $57.0 million. The Series C marked the latest financing event and included EQT Life Sciences and Gimv as lead investors. Product expansion became more explicit with the 2025 introduction of PSG-as-a-Service, extending the business beyond device sales toward a recurring or service-enabled model for remote clinical studies. Clinical publications in 2025 and 2026, the 2025 SleepTech Award, and the 2026 Somnoware integration indicate increasing emphasis on evidence and provider workflows. Employee data remains broad rather than precise, placing the organization in the 11–50 employee range. Public information does not establish revenue, hiring volume, or customer growth, limiting confidence in the scale of its commercial expansion.